![](https://tracker.live.rns-distribution.com/track.live-rns/5272470_d9353a075fe0b610698e373da828b7e4.png)
Rothschild & Co Continuation Finance PLC
Half-yearly Report for the six-month period ended 30 June 2024
Interim Management Report
Summary of Important Events
Rothschild & Co Continuation Finance PLC (the "Company") is a wholly-owned subsidiary of N. M. Rothschild & Sons Limited ("NMR") and was incorporated on 30 August 2000 to operate as a finance vehicle for the benefit of NMR and its subsidiaries.
The principal activity of the Company is the raising of finance for the purpose of lending it to NMR and other companies in NMR's group (the "Group"). The Company raises finance by the issue of perpetual subordinated notes guaranteed by NMR.
Risks and Uncertainties
The principal risks of the Company are credit risk, liquidity risk and market risk. The Company follows the risk management policies of the parent undertaking, NMR.
The Company's principal risk is credit exposure to NMR, as the notes issued by the Company have been guaranteed by, and funds have been on-lent to NMR. The Company is therefore reliant on the ability of NMR to meet its obligations under these lending arrangements. NMR is exposed to current market and geopolitical headwinds but, nevertheless, has sufficient liquidity to continue to operate for the next 12 months even in the scenario where revenue is significantly reduced. Management has considered the going concern basis of preparation as outlined in note 1 to the financial statements.
This half-yearly financial report has not been audited or reviewed by the Company's auditors pursuant to the Auditing Practices Board guidance on Review of Interim Financial Information.
Responsibilities Statement
The Directors confirm that to the best of their knowledge:
- | The condensed set of financial statements has been prepared in accordance with IAS 34 Interim Financial Reporting; and
|
- | The interim management report includes a fair review of (i) the important events that have occurred during the first six months of the financial year, and their impact on the condensed set of financial statements, and (ii) the principal risks and uncertainties for the remaining six months of the financial year. |
By Order of the Board
Peter Barbour
Director
18/07/2024
Condensed Interim Statement of Comprehensive Income
For the six months ended 30 June 2024
| | 6 months to | 6 months to |
| | 30 June | 30 June |
| Note | £ | £ |
Interest income | | 2,128,839 | 2,053,754 |
Interest expense | | (2,128,773) | (2,042,487) |
Operating profit |
| 66 | 11,267 |
Revaluation of loans | 4 | 8,007,360 | (3,476,570) |
Revaluation of debt securities | 9 | (8,011,889) | 3,470,275 |
Foreign exchange translation (losses)/gains | | 9,098 | (7,337) |
Profit/(loss) before tax |
| 4,635 | (2,365) |
Taxation | 3 | (27) | (4,084) |
Profit/(loss) for the financial period |
| 4,608 | (6,449) |
Other comprehensive income | | - | - |
Total comprehensive income/(loss) for the financial period |
| 4,608 | (6,449) |
Condensed Interim Statement of Changes in Equity
For the six months ended 30 June 2024
|
Share Capital | Retained Earnings | Total shareholders' equity |
| £ | £ | £ |
At 1 January 2024 | 100,000 | 317,636 | 417,636 |
Total comprehensive income for the period | - | 4,608 | 4,608 |
At 30 June 2024 | 100,000 | 322,244 | 422,244 |
| | | |
At 1 January 2023 | 100,000 | 324,190 | 424,190 |
Total comprehensive loss for the period | - | (6,449) | (6,449) |
At 30 June 2023 | 100,000 | 317,741 | 417,741 |
Condensed Interim Balance Sheet
At 30 June 2024
| | At 30 June | At 31 December | ||
| | 2024 | 2024 | 2023 | 2023 |
| Note | £ | £ | £ | £ |
Non-current assets | | | | | |
Loan to parent undertaking | 4 | | 97,284,560 | | 89,277,200 |
Current assets | | | | | |
Other financial assets | 5 | 721,582 | | 713,960 | |
Cash and cash equivalents | 6 | 267,050 | | 268,360 | |
|
| 988,632 |
| 982,320 | |
Current liabilities | | | | | |
Current tax liability | | (1,448) | | (1,904) | |
Deferred tax liability | 7 | (46,327) | | (45,844) | |
Other financial liabilities | 8 | (709,155) | | (712,007) | |
Net current assets |
|
| 231,702 |
| 222,565 |
Total assets less current liabilities | 97,516,262 | | 89,499,765 | ||
Non-current liabilities | | | | | |
Debt securities in issue | 9 | | (97,094,018) | | (89,082,129) |
Net assets |
|
| 422,244 |
| 417,636 |
Shareholders' equity | | | | | |
Share capital | 11 | | 100,000 | | 100,000 |
Retained earnings | | | 322,244 | | 317,636 |
Total shareholders' equity |
|
| 422,244 | | 417,636 |
Condensed Interim Cash Flow Statement
For the six months ended 30 June 2024
| | 6 months to | 6 months to |
| | 30 June | 30 June |
| Note | £ | £ |
Cash flow from operating activities | | | |
Net profit/(loss) for the financial period | | 4,608 | (6,449) |
Taxation | | 27 | 4,084 |
Net cash inflow/(outflow) from operating activities | | 4,635 | (2,365) |
Cash flow from financing activities Net increase/(decrease) in loans and interest receivable | |
(8,014,982) |
3,473,234 |
Net increase/(decrease) in debt securities in issue and interest payable | |
8,009,037 |
(3,466,913) |
Net cash (outflow)/inflow from financing activities | | (5,945) | 6,321 |
Net (decrease)/increase in cash and cash equivalents |
|
(1,310) |
3,956 |
Cash and cash equivalents at beginning of half-year | | 268,360 | 265,057 |
Cash and cash equivalents at end of half-year | 6 | 267,050 | 269,013 |
Interest receipts and payments during the period were as follows:
| 6 months to | 6 months to |
| 30 June 2024 | 30 June 2023 |
| £ | £ |
Interest received from parent undertaking | 2,121,217 | 2,050,418 |
Interest paid to note holders | 2,131,625 | 2,039,125 |
The Notes to the Condensed Interim Financial Statements form an integral part of the Condensed Interim Financial Statements.
Notes to the Condensed Interim Financial Statements
(forming part of the Condensed Interim Financial Statements)
For the six months ended 30 June 2024
1. Basis of Preparation
The Condensed Interim Financial Statements are prepared and approved by the Directors in accordance with IAS 34 Interim Financial Reporting. The Condensed Interim Financial Statements are prepared under the historical cost accounting rules and should be read in conjunction with the annual financial statements for the year ended 31 December 2023, which have been prepared in accordance with International Financial Reporting Standards.
The accounting policies and methods of valuation are identical to those applied in the financial statements for the year ended 31 December 2023.
Going Concern
Management has performed an assessment to determine whether there are any material uncertainties that could cast significant doubt on the ability of the Company to continue as a going concern. No significant issues have been noted. In reaching this conclusion, management considered:
- | The financial impact of the uncertainty on the Company's balance sheet;
|
- | The Company's liquidity position based on current and projected cash resources. The liquidity position has been assessed taking into account the forecast liquidity of NMR and its ability to continue to pay the interest on the intercompany loan provided by the Company. |
Based on the above assessment of the Company's financial position, the Directors have concluded that the Company has adequate resources to continue in operational existence for the foreseeable future (for a period of at least twelve months after the date that the financial statements are signed). Accordingly, they continue to adopt the going concern basis of accounting in preparing the annual financial statements.
Financial Risk Management
The Company follows the financial risk management policies of the parent undertaking, NMR. The key risks arising from the Company's activities involving financial instruments, which are monitored at the Group level, are as follows:
- | Credit risk - the risk of loss arising from client or counterparty default is not considered a significant risk to the Company as all asset balances are with other group companies as detailed in Note 12 Related Party Transactions.
|
- | Market risk - exposure to changes in market variables such as interest rates, currency exchange rates, equity and debt prices is not considered significant as the terms of financial assets substantially match those of financial liabilities.
|
- | Liquidity risk - the risk that the Company is unable to meet its obligations as they fall due or that it is unable to fund its commitments is not considered significant as the risk has been transferred to NMR. As the funds on-lent to NMR have the same maturity dates as the notes issued, the Company's ability to meet its obligations in respect of notes issued by it is affected by NMR's ability to make payments to the Company. |
2. Directors' Emoluments
None of the directors received any remuneration in respect of their services to the Company during the period (2023: £nil).
3. Taxation
| 6 months to | 6 months to 30 June 2023 |
| £ | £ |
Current tax | (1,159) | 520 |
Deferred tax | 1,132 | (4,604) |
Total tax | (27) | (4,084) |
The tax charge can be explained as follows:
| 6 months to | 6 months to |
| 30 June 2024 | 30 June 2023 |
| £ | £ |
Profit/(loss) before tax | 4,635 | (2,365) |
United Kingdom corporation tax credit/(charge) at effective rate 25% | (1,159) | 520 |
Deferred tax income statement charge | 1,132 | (4,604) |
Tax charged for the period | (27) | (4,084) |
4. Non-Current Assets: Loan to Parent Undertaking
| At 30 June | At 31 December |
| 2024 | 2023 |
| £ | £ |
At beginning of period | 89,277,200 | 92,848,908 |
Fair value movements | 8,007,360 | (3,571,708) |
At end of period | 97,284,560 | 89,277,200 |
Due |
|
|
In 5 years or more | 97,284,560 | 89,277,200 |
IFRS 9 requires the €150,000,000 loan to be carried at fair value which as at 30 June 2024 was £97,284,560 (at 31 December 2023: £89,277,200). On an amortised cost basis, the value of the loan at 30 June 2024 would be £127,028,217 (at 31 December 2023: £130,046,904). The fair values are based on the market value of the external debt securities (level 2).
The interest rate charged on the €150 million loan is EUR-TEC10-CNO plus 36 basis points, capped at 9.01% fixed on 05 February, 05 May, 05 August and 05 November each year. The interest rate on the above loan at 30 June 2024 was 3.41% (31 December 2023: 3.66%).
5. Current Assets: Other Financial Assets
| At 30 June | At 31 December |
| 2024 | 2023 |
| £ | £ |
Interest receivable | 721,582 | 713,960 |
6. Cash and Cash Equivalents
At 30 June 2024 the Company held cash of £267,050 (31 December 2023: £268,360) at the parent undertaking.
7. Deferred Income Taxes
| At 30 June | At 31 December |
| 2024 | 2023 |
| £ | £ |
At beginning of period | (45,844) | (37,915) |
Recognised in income: Income statement charge |
(483) | (7,929) |
At end of period | (46,327) | (45,844) |
Deferred tax assets less liabilities are attributable to the following items:
| At 30 June 2024 | At 31 December 2023 |
| £ | £ |
Fair value of intra group loans | 7,435,914 | 9,580,879 |
Fair value of debt securities in issue | (7,482,241) | (9,626,723) |
| (46,327) | (45,844) |
Both the intra-group loans and debt securities in issue are taxed on an amortised cost basis of accounting and accordingly taxable/deductible temporary differences arise following the adoption of IFRS 9.
8. Current Liabilities: Other Financial Liabilities
| At 30 June | At 31 December |
| 2024 | 2023 |
| £ | £ |
Interest payable | 709,155 | 712,007 |
9. Non-Current Liabilities: Debt Securities in Issue
| At 30 June | At 31 December |
| 2024 | 2023 |
| £ | £ |
At beginning of period | 89,082,129 | 92,649,367 |
Fair value movements | 8,011,889 | (3,567,238) |
At end of period | 97,094,018 | 89,082,129 |
Due |
| |
In 5 years or more | 97,094,018 | 89,082,129 |
Given the IFRS 9 requirement to fair value the related loans, the Company has elected to fair value the debt securities in issue, which as at 30 June 2024 was £97,094,018 (at 31 December 2023: £89,082,129). On an amortised cost basis, the value of the debt securities in issue at 30 June 2024 would be £127,028,217 (at 31 December 2023: £130,046,904). Consistent with the prior period, the fair value was derived from quoted market prices at the balance sheet date. In accordance with IFRS 13 and due to a reduction in the frequency and volume of transactions observed in the immediate run up to the period end, the fair value is considered to be level 2 as at 30 June 2024 (2023: level 2).
The interest rate payable on the €150 million Perpetual Subordinated Notes is EUR-TEC10-CNO plus 35 basis points, capped at 9 per cent, fixed on 05 February, 05 May, 05 August and 05 November each year. From and including the interest payment date falling in August 2016 and every interest payment date thereafter, the Company may redeem all (i.e. not in part) of the Perpetual Subordinated Notes at their principal amount.
The interest rate on the above notes at 30 June 2024 was 3.40% (31 December 2023: 3.65%).
10. Maturity of Financial Liabilities
The following table shows contractual cash flows payable by the Company on the perpetual subordinated notes classified by remaining contractual maturity at the balance sheet date. Interest cash flows on perpetual subordinated notes are shown up to five years only, with the principal balance being shown in the perpetual column.
At 30 June 2024
| | 3 months | | | | |
| | or less | 1 year | 5 years | | |
| | but not | or less | or less | | |
| | payable on | but over | but over | | |
| Demand | demand | 3 months | 1 year | Perpetual | Total |
| £ | £ | £ | £ | £ | £ |
Perpetual subordinated notes |
- |
1,079,740 |
3,239,220 |
17,275,838 |
127,028,217 |
148,623,015 |
At 31 December 2023
| | 3 months | | | | |
| | or less | 1 year | 5 years | | |
| | but not | or less | or less | | |
| | payable on | but over | but over | | |
| Demand | demand | 3 months | 1 year | Perpetual | Total |
| £ | £ | £ | £ | £ | £ |
Perpetual subordinated notes | - | 1,186,678 | 3,560,034 | 18,986,848 | 130,046,904 | 153,780,464 |
11. Share Capital
| At 30 June | At 31 December |
| 2024 | 2023 |
| £ | £ |
Authorised, allotted, called up and fully paid | | |
100,000 Ordinary shares of £1 each | 100,000 | 100,000 |
12. Related Party Transactions
Parties are considered to be related if one party controls, is controlled by or has the ability to exercise significant influence over the other party. This includes key management personnel, the parent company, subsidiaries and fellow subsidiaries.
Amounts receivable from related parties at the period end were as follows:
| At 30 June | At 31 December |
| 2024 | 2023 |
| £ | £ |
Cash and cash equivalents at parent undertaking | 267,050 | 268,360 |
Accrued interest receivable from parent undertaking | 721,582 | 713,960 |
Loans to parent undertaking | 97,284,560 | 89,277,200 |
Amounts recognised in the condensed statement of comprehensive income in respect of related party transactions were as follows:
| 6 months to | 6 months to |
| 30 June 2024 | 30 June 2023 |
| £ | £ |
Interest income from parent undertaking | 2,128,839 | 2,053,754 |
There were no loans made to Directors during the period (6 months to 30 June 2023: none) and no balances outstanding at the period end (at 31 December 2023: £nil). There were no employees of the Company during the period (6 months to 30 June 2023: none).
13. Parent Undertaking and Ultimate Holding Company and Registered Office
The largest group in which the results of the Company are consolidated is that headed by Rothschild & Co Concordia SAS, incorporated in France, and whose registered office is at 23bis, Avenue de Messine, 75008 Paris. The smallest group in which they are consolidated is that headed by Rothschild & Co SCA, a French public limited partnership whose registered office is also at 23bis, Avenue de Messine, 75008 Paris. The accounts are available on the Rothschild & Co website at www.rothschildandco.com.
The Company's immediate parent company is N. M. Rothschild and Sons Limited, incorporated in England and Wales and whose registered office is at New Court, St Swithins Lane, London, EC7N 8AL.
The Company's registered office is located at New Court, St Swithin's Lane, London, EC4N 8AL.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.